Beam Therapeutics Inc. Common Stock
BEAMStock
$28.39+57.51%52W
Market Cap$2.87B
P/E—
Div yield—
Beta2.20
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-2.86%
Price vs S&P 500 (4W)-1.08%
VGM Score63.40
Market Capitalization$2.87B
Earnings Surprise History
Q1 26-0.91est. -1.12
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.32
4.32
4.32
4.32
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BEAMBeam Therapeutics Inc. Common Stock | D | A | C | $28.39 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Beam Therapeutics is a precision genetic medicine company leveraging proprietary base editing technology to develop lifelong cures for serious diseases. The company's pipeline focuses on hematologic and genetic disorders, with lead programs including BEAM-101 for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency. Operations are based in the United States.